{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=83", "query": { "condition": "Solid Tumor Malignancies, Cancer", "page": 83 }, "page_size": 10 }, "pagination": { "page": 83, "page_size": 10, "total_count": 5467, "total_pages": 547, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=84&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=82&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T01:26:54.319Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Colorectal Cancer", "Advanced Pancreatic Ductal Adenocarcinoma", "Advanced Gastric Cancer", "Advanced Gastroesophageal Junction Cancer", "Advanced Esophageal Adenocarcinoma" ], "interventions": [ { "name": "BGB-53038", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2024-12-13", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 4, "location_summary": "Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585488" }, { "nct_id": "NCT00320073", "title": "Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-08", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320073" }, { "nct_id": "NCT03832569", "title": "Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumors", "Identified by NGS, PCR or IHC" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2019-02-20", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832569" }, { "nct_id": "NCT01123005", "title": "Imaging and Biomarkers of Hypoxia in Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PET Scan", "type": "PROCEDURE" }, { "name": "EF5", "type": "DRUG" }, { "name": "Carbogen", "type": "DRUG" }, { "name": "Dichloroacetate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-12", "completion_date": "2015-08-21", "has_results": false, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01123005" }, { "nct_id": "NCT04617522", "title": "Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor", "Liver Failure" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-04-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 8, "location_summary": "Long Beach, California • Newark, Delaware • Baltimore, Maryland + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04617522" }, { "nct_id": "NCT00071045", "title": "Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neoplasms", "Hematologic Neoplasms", "Healthy Volunteers" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "2 Years to 100 Years" }, "enrollment_count": 6000, "start_date": "2003-10-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071045" }, { "nct_id": "NCT00020202", "title": "FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Recurrent Small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Recurrent Non-small Cell Lung Cancer" ], "interventions": [ { "name": "FR901228", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020202" }, { "nct_id": "NCT00458731", "title": "Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Progressive Hairy Cell Leukemia, Initial Treatment", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Childhood Anaplastic Large Cell Lymphoma", "Stage IV Childhood Hodgkin Lymphoma", "Stage IV Childhood Large Cell Lymphoma", "Stage IV Childhood Lymphoblastic Lymphoma", "Stage IV Childhood Small Noncleaved Cell Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IVA Mycosis Fungoides/Sezary Syndrome", "Stage IVB Mycosis Fungoides/Sezary Syndrome", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cediranib maleate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 57, "start_date": "2007-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-19", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458731" }, { "nct_id": "NCT00183742", "title": "Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Carcinoma" ], "interventions": [ { "name": "liposomal doxorubicin and docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-12", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00183742" }, { "nct_id": "NCT06700070", "title": "A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Soft Tissue Sarcoma Adult", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PBA-0111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pure Biologics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-03-27", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-11-06T01:26:54.319Z", "location_count": 1, "location_summary": "Shreveport, Louisiana", "locations": [ { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06700070" } ] }